XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2024
Segment Reporting  
Schedule of financial information by reporting segment

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2024

2023

2024

2023

(in thousands)

Net revenues:

    

    

    

    

    

    

    

    

 

Finished pharmaceutical products

$

189,752

$

176,366

$

538,755

$

455,242

API

 

1,462

4,190

6,689

11,048

Total net revenues

 

191,214

 

180,556

 

545,444

 

466,290

Gross profit (loss):

Finished pharmaceutical products

 

105,544

 

109,499

 

302,322

 

262,742

API

 

(3,603)

(1,096)

(15,115)

(7,761)

Total gross profit

 

101,941

 

108,403

 

287,207

 

254,981

Operating expenses

 

44,893

 

35,725

 

126,932

 

111,974

Income from operations

 

57,048

 

72,678

 

160,275

 

143,007

Non-operating (expenses) income

 

(9,365)

 

(9,041)

 

(14,473)

 

(12,993)

Income before income taxes

$

47,683

$

63,637

$

145,802

$

130,014

Schedule of net revenues in the finished pharmaceutical products segment

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2024

2023

2024

2023

(in thousands)

Finished pharmaceutical products segment net revenues:

    

    

    

    

    

    

 

BAQSIMI®

$

40,409

$

$

85,106

$

Glucagon

26,792

29,514

82,700

82,486

Epinephrine

21,341

20,199

75,392

57,004

Primatene MIST®

26,055

24,834

73,077

64,837

Lidocaine

15,884

15,522

41,457

43,174

Phytonadione

11,721

7,449

31,998

33,017

Enoxaparin

 

5,615

 

7,702

 

17,984

25,441

Naloxone

4,037

4,715

12,124

14,774

Other finished pharmaceutical products

 

35,503

 

37,730

 

99,309

 

105,808

Total finished pharmaceutical products net revenues

187,357

147,665

519,147

426,541

BAQSIMI® NEB

2,395

28,701

19,608

28,701

Total finished pharmaceutical products segment net revenues

$

189,752

$

176,366

$

538,755

$

455,242

Schedule of depreciation and amortization expense by reporting segment

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2024

2023

2024

2023

(in thousands)

Depreciation and amortization expense

    

    

    

    

    

    

    

    

 

Finished pharmaceutical products

$

8,755

$

8,616

$

26,086

$

13,143

API

 

1,038

 

1,003

 

3,045

2,938

Total depreciation and amortization expense

$

9,793

$

9,619

$

29,131

$

16,081

Schedule of net revenues and carrying values of long-lived assets by geographic region

Net Revenues

Long-Lived Assets

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

September 30, 

December 31, 

2024

2023

2024

2023

2024

2023

(in thousands)

United States(1)

    

$

186,514

    

$

178,056

    

$

532,591

    

$

459,909

    

$

187,410

    

$

186,083

China

 

178

833

2,145

2,142

 

103,009

 

91,913

France

 

4,522

1,667

10,708

4,239

 

37,099

 

37,647

Total

$

191,214

$

180,556

$

545,444

$

466,290

$

327,518

$

315,643